CYTX Cytori Therapeutics Inc

1.03
-0.01  -1%
Previous Close 1.04
Open 1.05
Price To book 3.35
Market Cap 24.48M
Shares 23,767,000
Volume 410,451
Short Ratio 1.99
Av. Daily Volume 770,106

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Announced mid-January 2016 that first patients have been enrolled
Cytori Cell Therapy
Crohn’s Disease
Data are due early 3Q 2017. BPC estimate end of July as latest likely date.
ECCS-50
Scleroderma
Phase 2 interim data released February 2016 noted that the pre-specified primary endpoint did not obtain statistical significance. Full data due 3Q 2016
ECCO-50 cellular therapeutic
Osteoarthritis of the knee
Enrolling
Cell Enriched Adipose
Early stage female and male pattern hair loss

Latest News

  1. ETFs with exposure to Cytori Therapeutics, Inc. : May 25, 2017
  2. Cytori Therapeutics, Inc. :CYTX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 24, 2017
  3. Cytori Logs Final 48 Week Patient Follow Up Visit in Scleroderma Trial
  4. Edited Transcript of CYTX earnings conference call or presentation 11-May-17 9:30pm GMT
  5. Cytori Provides Latest Corporate Update at the 18th Annual B. Riley & Co. Institutional Investor Conference
  6. Cytori reports 1Q loss
  7. Cytori Reports First Quarter 2017 Business and Financial Results
  8. One Year Follow Up of Cytori Cell Therapy™ in Investigator Erectile Dysfunction Trial
  9. Cytori Therapeutics Announces Inducement Grants for New Employees
  10. Cytori to Webcast First Quarter Financial Results on May 11
  11. Cytori Therapeutics Stock Sliding on Offering Price Discount
  12. Cytori Therapeutics' stock plunges toward record low after stock offering prices at deep discount
  13. Cytori Announces Pricing of $9.5M Public Offering of Common Stock
  14. Today's Research Reports on Biotech Stocks to Watch: Cytori Therapeutics and Geron
  15. Cytori Announces Proposed Public Offering of Common Stock
  16. Cytori Get FDA Approval for Clinical Burn Trial
  17. ETFs with exposure to Cytori Therapeutics, Inc. : April 10, 2017
  18. Cytori Rises on Crucial FDA Approval
  19. Cytori Receives U.S. FDA Approval for Burn Clinical Trial Related to BARDA Contract
  20. Cytori Appoints Gregg Lapointe to Board of Directors

SEC Filings

  1. 8-K - Current report 17861878
  2. S-3 - Registration statement under Securities Act of 1933 17840062
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 17840005
  4. 8-K - Current report 17834787
  5. 424B3 - Prospectus [Rule 424(b)(3)] 17785431
  6. EFFECT - Notice of Effectiveness 17782371
  7. CT ORDER - Confidential treatment order 17777232
  8. 8-K - Current report 17758595
  9. 424B5 - Prospectus [Rule 424(b)(5)] 17758576
  10. DEF 14A - Other definitive proxy statements 17754227